title: Initial oxygenation response to inhaled nitric oxide predicts improved outcome in congenital diaphragmatic hernia.
abstract: BACKGROUND
  Pulmonary hypertension (PH) is the most important complication of congenital diaphragmatic hernia (CDH) and still has a high mortality rate. The aim of this study was to evaluate the effectiveness of inhaled nitric oxide therapy in PH due to CDH.
  
  
  METHODS
  Hospital records of children who had undergone inhaled nitric oxide therapy for PH due to CDH between June 2009 and December 2011 were reviewed.
  
  
  RESULTS
  Twenty-nine patients had a diagnosis of CDH at the time of study, and eight of these patients underwent nitric oxide therapy because of failure of conventional ventilation techniques, which was successful in five of these patients. Patients who had a good overall outcome of nitric oxide therapy experienced rapid improvement (pretreatment, mean PaO2 = 44.8 mmHg; after the first hour of therapy, mean PaO2 = 96.8 mmHg), whereas patients with no response did not have a similar course (pretreatment, PaO2 = 37 mmHg; after the first hour, PaO2 = 54.6 mmHg).
  
  
  CONCLUSIONS
  Inhaled nitric oxide therapy seems to increase survival in PH due to CDH. No predictive parameters to orient patient selection could be identified; however, the early response seemed to predict the overall outcome. Good results in our series were attributed to routine use of sildenafil and dopamine, along with the nitric oxide inhalation.
authors.affiliation: Hacettepe University, Ankara, Turkey, tiryakisibel@gmail.com.
authors.forename: Sibel
authors.initials: S
authors.lastname: Tiryaki
authors.forename: Coskun
authors.initials: C
authors.lastname: Ozcan
authors.forename: Ata
authors.initials: A
authors.lastname: Erdener
mesh_terms: D000280:Administration, Inhalation; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004298:Dopamine / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D065630:Hernias, Diaphragmatic, Congenital / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D007441:Intubation, Gastrointestinal; D009569:Nitric Oxide / Q000008:administration & dosage / Q000627:therapeutic use*; D010100:Oxygen / Q000097:blood*; D012189:Retrospective Studies; D000068677:Sildenafil Citrate / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D010100:Oxygen; D004298:Dopamine